Retatrutide — Research Summary

Research Use Only · Not for Human or Veterinary Use

Triple hormone receptor agonist (GLP-1/GIP/glucagon) studied for advanced metabo

Retatrutide

An evidence summary of published preclinical research on Retatrutide. This page is educational and summarizes findings reported in third-party scientific literature. No claims are made regarding safety or efficacy in humans.

Molecular Data

FORMULA C228H358N50O67
MOLECULAR WEIGHT 5,098.7 g/mol
SEQUENCE 39-amino acid triple agonist peptide

Compound Overview

Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. It represents the next evolution beyond dual agonists like tirzepatide by adding glucagon receptor activation. Phase II clinical trial results showed unprecedented weight loss efficacy, generating significant interest in the metabolic research community.

Reported Mechanism (Preclinical)

Retatrutide activates three distinct metabolic receptors: GLP-1R (promoting satiety, insulin secretion, and slowed gastric emptying), GIPR (enhancing insulin sensitivity and fat metabolism), and GCGR (glucagon receptor, stimulating hepatic glycogenolysis, lipolysis, and thermogenesis). The glucagon component is the key differentiator — it increases energy expenditure and hepatic fat oxidation. The triple mechanism produces synergistic metabolic effects exceeding dual agonists.

Mechanisms described above are reported in preclinical (animal and in vitro) literature and have not been established for human use.

Key Research Highlights

  • Phase II trial demonstrated up to 24.2% body weight reduction at 48 weeks (Jastreboff et al., 2023)
  • Showed superior weight loss compared to dual agonist approaches in head-to-head preclinical comparisons
  • Significant reductions in liver fat content observed in trial participants with NAFLD
  • Demonstrated improvements in glycemic control (HbA1c) in participants with type 2 diabetes
  • Glucagon receptor agonism contributed to increased energy expenditure and thermogenesis

Published References

  1. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
    N Engl J Med, 2023
  2. Retatrutide, a GGG tri-agonist, for type 2 diabetes
    N Engl J Med, 2023
  3. GLP-1/GIP/glucagon triple receptor agonism: a new paradigm in obesity therapy
    Lancet Diabetes Endocrinol, 2023

Available for Research

Lab-tested, third-party COA published, U.S. ships same day.

View Product · Retatrutide View COA Library
Compliance Notice: American Peptides products are sold strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature, summarizes findings from preclinical literature, and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution's safety protocols and applicable laws.